15.53

1.85% -0.25

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $15.53, with a volume of 330.93K. It is down -1.85% in the last 24 hours and down -16.55% over the past month. Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Previous Close:

$15.78

Open:

$15.77

24h Volume:

330.93K

Relative Volume:

0.23

Market Cap:

$1.60B

Revenue:

$54.55M

Net Income/Loss:

$-193.57M

P/E Ratio:

-5.3737

EPS:

-2.89

Net Cash Flow:

$-181.86M

1W Performance:

-0.72%

1M Performance:

-16.55%

6M Performance:

+52.74%

1Y Performance:

-8.19%

1-Day Range:

$15.47

$16.49

1-Week Range:

$15.06

$16.49

52-Week Range:

$8.18

$22.50

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1117)

Industry

Biotechnology (619)

Phone

(415) 660-5320

Address

1600 SIERRA POINT PKWY, BRISBANE

Employee

357

Twitter

Next Earnings Date

2025-10-09

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	15.55	1.62B	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	485.77	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	784.21	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	829.07	52.25B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	330.72	44.59B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	366.39	40.07B	4.98B	69.60M	525.67M	0.5198

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Feb 22, 2026

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - Yahoo Finance

Feb 22, 2026

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool

Feb 22, 2026

Feb 21, 2026